Mills Ch3 Breast

84

SECTION II : Breast

81. Bailey AJ, Sloane JP, Trickey BS, et al. An immunocyto- chemical study of alpha-lactalbumin in human breast tissue. J Pathol 1982;137(1):13–23. 82. Mazoujian G, Pinkus GS, Davis S, et al. Immunohistochem- istry of a gross cystic disease fluid protein (GCDFP-15) of the breast. A marker of apocrine epithelium and breast carcinomas with apocrine features. Am J Pathol 1983;110(2):105–112. 83. Sasaki E, Tsunoda N, Hatanaka Y, et al. Breast-specific expression of MGB1/mammaglobin: an examination of 480 tumors from various organs and clinicopathological analysis of MGB1-positive breast cancers. Mod Pathol 2007;20(2): 208–214. 84. Chui X, Egami H, Yamashita J, et al. Immunohistochemical expression of the c-kit proto-oncogene product in human malignant and non-malignant breast tissues. Br J Cancer 1996; 73(10):1233–1236. 85. Simone NL, Paweletz CP, Charboneau L, et al. Laser capture microdissection: Beyond functional genomics to proteomics. Mol Diagn 2000;5(4):301–307. 86. Deng G, Lu Y, Zlotnikov G, et al. Loss of heterozygos- ity in normal tissue adjacent to breast carcinomas. Science 1996;274(5295):2057–2059. 87. Lakhani SR, Chaggar R, Davies S, et al. Genetic alterations in ‘normal’ luminal and myoepithelial cells of the breast. J Pathol 1999;189(4):496–503. 88. Larson PS, de las Morenas A, Cupples LA, et al. Genetically abnormal clones in histologically normal breast tissue. Am J Pathol 1998;152(6):1591–1598. 89. Larson PS, de las Morenas A, Bennett SR, et al. Loss of heterozygosity or allele imbalance in histologically normal

breast epithelium is distinct from loss of heterozygosity or allele imbalance in co-existing carcinomas. Am J Pathol 2002; 161(1):283–290. 90. Graham K, Ge X, de Las Morenas A, et al. Gene expression profiles of estrogen receptor-positive and estrogen receptor- negative breast cancers are detectable in histologically normal breast epithelium. Clin Cancer Res 2011;17(2):236–246. 91. Dontu G, Al-Hajj M, Abdallah WM, et al. Stem cells in nor- mal breast development and breast cancer. Cell Prolif 2003; 36(Suppl 1):59–72. 92. Sarrio D, Franklin CK, Mackay A, et al. Epithelial and mes- enchymal subpopulations within normal basal breast cell lines exhibit distinct stem cell/progenitor properties. StemCells 2012; 30(2):292–303. 93. Keller PJ, Arendt LM, Skibinski A, et al. Defining the cellular precursors to human breast cancer. Proc Natl Acad Sci U S A 2012;109(8):2772–2777. 94. Sgroi DC, Teng S, Robinson G, et al. In vivo gene expression profile analysis of human breast cancer progression. Cancer Res 1999;59(22):5656–5661. 95. Perou CM, Jeffrey SS, van de Rijn M, et al. Distinctive gene expression patterns in human mammary epithelial cells and breast cancers. Proc Natl Acad Sci U S A 1999;96(16): 9212–9217. 96. Emmert-Buck MR, Strausberg RL, Krizman DB, et al. Molecular profiling of clinical tissue specimens: feasibility and applications. Am J Pathol 2000;156(4):1109–1115. 97. Espina V, Geho D, Mehta AI, et al. Pathology of the future: Molecular profiling for targeted therapy. Cancer Invest 2005; 23(1):36–46.